Differentiated Thyroid Carcinoma
📧 Sign up to get email alerts when something new happens for Differentiated Thyroid Carcinoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-09-12FDA Approved: SORAFENIB — Supplemental Application (Yabao Pharmaceutical Co., Ltd. Beijing)
FDA approved a supplemental application for Sorafenib by Yabao Pharmaceutical Co., Ltd. Beijing under an ANDA.
-
FDA approval · 2023-09-12FDA Approved: SORAFENIB — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for Sorafenib from Teva Pharmaceuticals, indicating regulatory action for the generic product. Soraf…
-
FDA approval · 2023-04-12FDA Approved: SORAFENIB — Original Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals' original ANDA for sorafenib, a generic version of Nexavar, expanding access to the cancer therapy.
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer [Phase 2]
Phase 2 trial of lenvatinib with iodine therapy for radioactive iodine–sensitive differentiated thyroid cancer has terminated; results poste…
-
FDA approval · 2022-11-09FDA Approved: SORAFENIB — Original Application (Yabao Pharmaceutical Co., Ltd. Beijing)
FDA approved a generic sorafenib product from Yabao Pharmaceutical Co., Ltd. Beijing (ANDA 209050). The approval covers the same indications…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-06-07FDA Approved: SORAFENIB — Original Application (Dr.Reddys Laboratories Inc)
FDA approves the original application for a generic sorafenib product from Dr. Reddy's Laboratories Inc, expanding access to the cancer drug…
-
CLINICAL_TRIALS trial_result · 2022-03-14Clinical Trial Update: Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma [Phase 4]
Phase 4 clinical study evaluating the effect of selenium yeast capsules on prognosis in differentiated thyroid carcinoma, with an unclear st…
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer [Phase 1, Phase 2]
Clinical trial update for cediranib maleate with or without lenalidomide in thyroid cancer completed; results posted in 2021.
-
FDA approval · 2021-06-11FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)
FDA approved a supplemental application for HICON (Sodium I-131) from Jubilant DraxImage Inc., dba Jubilant Radiopharma.
-
FDA approval · 2020-11-12FDA Approved: SORAFENIB — Original Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's original application for a generic sorafenib product, enabling a generic version of the cancer drug Sorafenib to be …
-
FDA approval · 2020-09-10FDA Approved: SORAFENIB TOSYLATE — Original Application (Mylan Pharmaceuticals Inc.)
The FDA approved a generic sorafenib tosylate product from Mylan under an original application. Sorafenib is indicated for hepatocellular ca…
-
FDA approval · 2020-05-08FDA Approved: RETEVMO — Original Application (Eli Lilly and Company)
FDA approved Retevmo (selpercatinib) from Eli Lilly in its original NDA. The approval covers RET fusion-positive non-small cell lung cancer …
-
FDA approval · 2020-03-12FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for THYROGEN (thyrotropin alfa) from Genzyme Corporation, updating the labeling to support its use i…
-
CLINICAL_TRIALS trial_result · 2020-02-13Clinical Trial Update: Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma [Phase 2]
Phase 2 study of sulfatinib for advanced medullary thyroid carcinoma and iodine-refractory differentiated thyroid carcinoma has completed.
-
CLINICAL_TRIALS research · 2018-07-16Clinical Trial Update: the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism [EARLY_Phase 1]
This early-phase clinical trial is investigating how the gut microbiota are associated with iodine-131 therapy and the development of hypoth…
-
FDA approval · 2018-06-06FDA Approved: LENVIMA — Supplemental Application (Eisai Inc.)
FDA approved a supplemental application for LENVIMA (lenvatinib) submitted by Eisai Inc.
-
FDA approval · 2017-12-22FDA Approved: NEXAVAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Nexavar (sorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2017-09-15Clinical Trial Update: Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery [Phase 2]
This Phase 2 trial evaluated Sunitinib malate in iodine-refractory thyroid cancers, including differentiated and medullary subtypes. Results…
-
CLINICAL_TRIALS trial_result · 2017-08-09Clinical Trial Update: Compare the Aesthetic Effect of Different Thyroidectomies [NA]
This clinical trial compared the aesthetic outcomes of different thyroidectomy techniques in Differentiated Thyroid Carcinoma, and the study…
-
CLINICAL_TRIALS research · 2017-05-30Clinical Trial Update: Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma [Phase 2]
Phase 2 clinical trial update for Apatinib Mesylate in Differentiated Thyroid Carcinoma; no results are reported yet and the trial status is…
-
FDA approval · 2017-04-24FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for THYROGEN (thyrotropin alfa) submitted by Genzyme Corporation. The action updates the labeling to…
-
FDA approval · 2017-02-24FDA Approved: TIROSINT SOL — Supplemental Application (IBSA Pharma Inc.)
The FDA approved a supplemental application for TIROSINT SOL (levothyroxine sodium) from IBSA Pharma Inc., a thyroid hormone replacement the…
-
CLINICAL_TRIALS trial_result · 2015-11-06Clinical Trial Update: Bioequivalence Study of Sorafenib Tablet and Nexavar [Phase 1]
A Phase 1 bioequivalence study comparing sorafenib tablet to Nexavar under fasting conditions has completed.
-
FDA approval · 2015-02-13FDA Approved: LENVIMA — Original Application (Eisai Inc.)
FDA approves LENVIMA (lenvatinib) in its original application for the treatment of differentiated thyroid carcinoma.
-
FDA approval · 2015-02-03FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)
FDA approved a supplemental application for HICON (Sodium iodide I-131) from Jubilant DraxImage Inc., dba Jubilant Radiopharma.